| Metric | Value ($ M) | Q2 FY26 | Q3 FY25 |
|---|---|---|---|
| Revenue | 9.07 | 24.4% | 29.8% |
| Total Income | 9.07 | 24.4% | 29.8% |
| Expenditure | 15.57 | 24.3% | 17.3% |
| PBT | -6.42 | 1006.9% | 3.3% |
| Net Profit | -6.42 | 970.0% | 3.5% |
| OPM | -71.63% | 67.27pp | 18.21pp |
| NPM | -70.82% | 65.78pp | 24.33pp |
| EPS | -0.42 | 740.0% | 32.3% |
Biofrontera Reports Strong Third Quarter 2026 Financial Results Driven by 30% Year-Over-Year Revenue Growth
13 Nov 2026 · 13 Nov, 6:46 pm
Summary
Biofrontera Inc. reported strong financial results for the third quarter of 2026, driven by a 29.8% year-over-year increase in net product revenue to $9.1 million. The company also saw significant improvements in gross margin, which rose to 74.4% from 70.7% in the prior year, attributed to a more favorable cost structure. While still reporting a net loss of $6.4 million, this represents an improvement from the previous year's loss. Management highlighted key regulatory approvals and the resolution of import issues as significant Q3 achievements, with plans to commercialize Ameluz® for sBCC in the upcoming quarters.
Key Highlights
- 1
Biofrontera Inc. reported net product revenue of $9.1 million for the third quarter of 2026, an increase of 29.8% compared to $7.0 million in the prior-year period.
- 2
Gross margin improved to 74.4% in Q3 2026, compared to 70.7% in the prior-year period, reflecting a lower Ameluz® cost structure.
- 3
The company reported a net loss of $6.4 million, or $(0.42) per share, for Q3 2026, an improvement from a net loss of $6.6 million, or $(0.62) per share, in the prior-year period.
- 4
Adjusted EBITDA for Q3 2026 was $(5.5) million, an improvement from $(6.0) million in the prior-year period.
- 5
Net product revenue for the nine months ended September 30, 2026 increased by 26.6% to $31.2 million from $24.6 million in the prior-year period.
- 6
Gross margin for the nine months ended September 30, 2026 was 78.0%, compared to 67.7% in the prior-year period.
- 7
The FDA approved Ameluz® on September 9, 2026, for the treatment of Superficial Basal Cell Carcinoma (sBCC), making it the first PDT approved in the United States for a cancerous skin tumor.
Management Comments
Hermann Luebbert
The third quarter was a pivotal one for Biofrontera. On September 9, the FDA approved Ameluz® PDT for the treatment of superficial basal cell carcinoma (sBCC), making it the first PDT approved in the United States for a cancerous skin tumor. Five days later, U.S. Customs and Border Protection ruled that our redesigned RhodoLED® XL-C is not subject to the ITC exclusion order, which allows us to again serve the customers who rely on our large-field lamp. Revenue grew 30% in the quarter and 27% for the first nine months, and our gross margin continues to reflect the lower cost structure we put in place with the Strategic Transaction. The quarter also carried the legal and remediation costs of the ITC Matter, and with the XL-C now cleared our attention is on execution. We are preparing to begin commercializing Ameluz® for sBCC later in the fourth quarter and into the first quarter of 2027, and in October we submitted a supplemental New Drug Application to expand the Ameluz® label for actinic keratosis to the extremities, neck and trunk. Each of these indications is served by the lamps and the sales force we already have in place.
Informational and educational content only. Not investment advice.